|Gastrointestinal symptoms in a sample of children with pervasive developmental disorders|
RN Nikolov, KE Bearss, J Lettinga, C Erickson, M Rodowski, MG Aman, ...
Journal of autism and developmental disorders 39 (3), 405-413, 2009
|Gastrointestinal factors in autistic disorder: a critical review|
CA Erickson, KA Stigler, MR Corkins, DJ Posey, JF Fitzgerald, ...
Journal of autism and developmental disorders 35 (6), 713, 2005
|Antipsychotics in the treatment of autism|
DJ Posey, KA Stigler, CA Erickson, CJ McDougle
The Journal of clinical investigation 118 (1), 6-14, 2008
|A retrospective study of memantine in children and adolescents with pervasive developmental disorders|
CA Erickson, DJ Posey, KA Stigler, J Mullett, AR Katschke, CJ McDougle
Psychopharmacology 191 (1), 141-147, 2007
|Atypical antipsychotics in children and adolescents with autistic and other pervasive developmental disorders|
CJ McDougle, KA Stigler, CA Erickson, DJ Posey
Journal of Clinical Psychiatry 69, 15, 2008
|Neurochemistry in the pathophysiology of autism|
CJ McDougle, CA Erickson, KA Stigler, DJ Posey
Journal of Clinical Psychiatry 66, 9, 2005
|Aggression in autism spectrum disorder: presentation and treatment options.|
SE Fitzpatrick, L Srivorakiat, LK Wink, EV Pedapati, CA Erickson
Dove Medical Press Ltd., 2016
|STX209 (arbaclofen) for autism spectrum disorders: an 8-week open-label study|
CA Erickson, JM Veenstra-Vanderweele, RD Melmed, JT McCracken, ...
Journal of autism and developmental disorders 44 (4), 958-964, 2014
|Aripiprazole in pervasive developmental disorder not otherwise specified and Asperger's disorder: a 14-week, prospective, open-label study|
KA Stigler, JT Diener, AE Kohn, L Li, CA Erickson, DJ Posey, ...
Journal of child and adolescent psychopharmacology 19 (3), 265-274, 2009
|Impact of acamprosate on behavior and brain-derived neurotrophic factor: an open-label study in youth with fragile X syndrome|
CA Erickson, LK Wink, B Ray, MC Early, E Stiegelmeyer, ...
Psychopharmacology 228 (1), 75-84, 2013
|The use of selective serotonin reuptake inhibitors in autism and related disorders|
DJ Posey, CA Erickson, KA Stigler, CJ McDougle
Journal of Child & Adolescent Psychopharmacology 16 (1-2), 181-186, 2006
|Pharmacologic treatment of behavioral symptoms associated with autism and other pervasive developmental disorders|
LK Wink, CA Erickson, CJ McDougle
Current Treatment Options in Neurology 12 (6), 529-538, 2010
|Drug-refractory aggression, self-injurious behavior, and severe tantrums in autism spectrum disorders: a chart review study|
BA Adler, LK Wink, M Early, R Shaffer, N Minshawi, CJ McDougle, ...
Autism 19 (1), 102-106, 2015
|SPARK: a US cohort of 50,000 families to accelerate autism research|
P Feliciano, AM Daniels, LAG Snyder, A Beaumont, A Camba, A Esler, ...
Neuron 97 (3), 488-493, 2018
|Diagnosing autism spectrum disorder from brain resting-state functional connectivity patterns using a deep neural network with a novel feature selection method|
X Guo, KC Dominick, AA Minai, H Li, CA Erickson, LJ Lu
Frontiers in neuroscience 11, 460, 2017
|Brief report: acamprosate in fragile X syndrome|
CA Erickson, JE Mullett, CJ McDougle
Journal of autism and developmental disorders 40 (11), 1412-1416, 2010
|Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole|
LK Wink, M Early, T Schaefer, A Pottenger, P Horn, CJ McDougle, ...
Journal of child and adolescent psychopharmacology 24 (2), 78-82, 2014
|Developing drugs for core social and communication impairment in autism|
DJ Posey, CA Erickson, CJ McDougle
Child and adolescent psychiatric clinics of North America 17 (4), 787-801, 2008
|Open-label riluzole in fragile X syndrome|
CA Erickson, N Weng, IJ Weiler, WT Greenough, KA Stigler, LK Wink, ...
Brain research 1380, 264-270, 2011
|Updated report on tools to measure outcomes of clinical trials in fragile X syndrome|
DB Budimirovic, E Berry-Kravis, CA Erickson, SS Hall, D Hessl, AL Reiss, ...
Journal of Neurodevelopmental Disorders 9 (1), 1-36, 2017